0 items

in your cart

Prescription Drug Search

Strengths available for Sirolimus :

Sirolimus 1mg

Strengths available for Sirolimus vial:

Sirolimus vial 1mg/mL

Search for a drug:


Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Sirolimus:

  • Antigua and Barbuda
  • Barbados
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Cayman Islands
  • China
  • Cook Islands
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Ecuador
  • Egypt
  • Grenada
  • Guatemala
  • India
  • Iraq
  • Japan
  • Korea, South
  • Mauritius
  • Moldova, Republic of
  • Morocco
  • Netherlands
  • New Zealand
  • Panama
  • Philippines
  • Qatar
  • Serbia
  • Seychelles
  • Singapore
  • South Africa
  • Sweden
  • Switzerland
  • Taiwan
  • Trinidad and Tobago
  • Ukraine
  • United Kingdom, UK
  • United States, US
  • Vanuatu
  • Venezuela
View All Countries

Latest news releases on Sirolimus:

Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer - Medscape News

Sirolimus has antineoplastic effects and may reduce skin cancer rates in kidney transplant patients. This prospective, multicenter, randomized, open-label, controlled trial randomized 86 kidney transplant recipients (≥1 year posttransplant ...

BK virus nephropathy in simultaneous pancreas kidney transplant: a potentially preventable cause of kidney allograft loss - Doctors Guide

All patients underwent rabbit anti-thymocyte globulin (rATG) induction and were maintained on tacrolimus/sirolimus or mycophenolate. The incidence of BKVN was 4.4%. BKVN was diagnosed at a median of 11 months; mean serum creatinine 2.1 mg/dL and ...

Post-SES Implantation, Statins Prevent Late Revascularization - Monthly Prescribing Reference

(HealthDay News) – For patients who undergo sirolimus-eluting stent (SES) implantation, use of statin therapy is associated with a reduced risk of late target lesion revascularization (TLR), according to a study published in the May 15 issue of The ...

Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent™ Compared to the TAXUS® … - Yahoo Finance

"The Combo Stent is the only technology that combines the value of endothelial progenitor cell capture to promote vessel healing with an abluminal sirolimus drug elution to limit neointimal proliferation," said Stephen M. Rowland, Ph.D., vice ...

Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study - Business Wire

DIRECT is a First-In-Man, multi-center clinical study designed to assess the feasibility of Svelte’s novel ‘All-In-One’ system which combines a thin-strut cobalt chromium stent with a fully bio-absorbable drug carrier and the well-studied sirolimus ...

OrbusNeich’s Combo Dual Therapy Stent Continues to Show Promise in Clinical Trial - Medagadget.com

The randomized REMEDEE trial (Randomized Evaluation of an abluMinal sirolimus coatED bio- Engineered stEnt) found that the Combo Dual Therapy stent was non-inferior to the TAXUS Liberté paclitaxel-eluting stent based on in-stent late lumen ...

Svelte completes enrollment in DIRECT drug-eluting stent study - News-Medical.Net

multi-center clinical study designed to assess the feasibility of Svelte's novel 'All-In-One' system which combines a thin-strut cobalt chromium stent with a fully bio-absorbable drug carrier and the well-studied sirolimus (rapamycin ...

Cordis Medical Device Company Intelligence Report - new company profile report - Transworld News

In 2003, the FDA approved the Cypher sirolimus-eluting coronary stent, the first combination drug-device product intended to help reduce restenosis, or "reclogging", of a treated coronary artery. Cordis signalled its commitment to continue stent innovation ...

OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up - Yahoo Finance

the only dual therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer ...

BIOTRONIK's Bioabsorbable Magnesium Scaffold Continues to Show Strong Results at 12 Months With Uncompromised Device Usability - Boston Globe

The company has announced next-generation platforms under development using the BIOlute(R) coating from the Orsiro hybrid drug-eluting stent featuring sirolimus as the active compound. About BIOTRONIK SE & Co. KG As one of the world's leading ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK